Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)

eagle-i ID

Resource Type

Properties

1. ClinicalTrials.gov url

   http://www.clinicaltrials.gov/ct2/show/NCT01015833?term=NCT01015833&rank=1

2. Intervention

   Sorafenib tosylate

3. Intervention

   Doxorubicin hydrochloride

4. Resource Description

   This randomized phase III trial is studying sorafenib tosylate and doxorubicin hydrochloride to see how well they work compared with sorafenib tosylate alone in treating patients with locally advanced or metastatic liver cancer.

5. Contact

   Berenberg, Jeffrey

6. PI

   Berenberg, Jeffrey

7. Topic

   liver cancer

8. Study Population

   Men and women at least 18 years old with no CNS tumors or brain metastases, no previous liver transplant or bone marrow transplant, and meeting other therapy-related criteria.

9. Funded by

   Cancer Trials Support Unit

10. Phase

    Phase 3 clinical trial

11. Performed by

    Clinical Protocol & Data Management Shared Resource